CNC vs MRNA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Centene Corporation exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 2/9, indicating poor financial health and deteriorating operational efficiency. While the company shows strong top-line revenue growth of 23.2%, this is completely offset by a catastrophic YoY EPS decline of -248.7% and a deeply negative ROE of -28.68%. The stock appears cheap on a Price-to-Sales (0.12) and Price-to-Book (1.07) basis, but these metrics likely reflect a 'value trap' given the negative profit margins and lack of earnings stability. Despite a recent short-term price rally, the long-term technical trend remains bearish and analyst targets are flat.
MRNA shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.
Compare Another Pair
Related Comparisons
CNC vs MRNA: Head-to-Head Comparison
This page compares Centene Corporation (CNC) and Moderna, Inc. (MRNA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.